HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis

This item is licensed under: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

Files in This Item:
1_Ohara_et_al-2018-Hepatology_Communications.pdf587.9 kBPDFView/Open
2_hep41207-sup-0001-supinfos1.docxSupporting Information15.15 kBMicrosoft Word XMLView/Open
3_hep41207-sup-0002-supinfos2.tifSupporting Information4.81 MBTIFFView/Open
Please use this identifier to cite or link to this item:

Title: L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
Authors: Ohara, Masatsugu Browse this author
Ogawa, Koji Browse this author
Suda, Goki Browse this author →KAKEN DB
Kimura, Megumi Browse this author
Maehara, Osamu Browse this author
Shimazaki, Tomoe Browse this author
Suzuki, Kazuharu Browse this author
Nakamura, Akihisa Browse this author
Umemura, Machiko Browse this author
Izumi, Takaaki Browse this author
Kawagishi, Naoki Browse this author
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Natsuizaka, Mitsuteru Browse this author
Morikawa, Kenichi Browse this author
Ohnishi, Shunsuke Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Issue Date: Aug-2018
Publisher: John Wiley & Sons
Journal Title: Hepatology communications
Volume: 2
Issue: 8
Start Page: 910
End Page: 922
Publisher DOI: 10.1002/hep4.1207
Abstract: Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited. In this retrospective study, 158 patients with LC were screened, and 35 of those patients who were treated with L-carnitine for more than 6 months and for whom skeletal muscle mass changes could he evaluated by computer tomography were enrolled. Of the 158 patients, 79 patients who did not receive L-carnitine supplementation served as controls. Cases and controls were propensity score matched for age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration, and changes in skeletal muscle mass and clinical data were compared. The 35 patients who received L-carnitine supplementation and 35 propensity score-matched patients who did not receive carnitine supplementation comprised the final enrollment. Compared with control patients, patients who received L-carnitine had significantly worse liver function, which is associated with rapid progress of skeletal muscle depletion. However, loss of skeletal muscle mass was significantly suppressed in patients receiving L-carnitine, and a significant effect was observed in patient subgroups stratified by age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration. The change ratios of most laboratory data, including vitamin D and insulin-like growth factor 1 levels, were similar in the two groups, but ammonia levels were significantly less in those receiving L-carnitine. However, even in patients receiving L-carnitine but not showing an ammonia decrease, loss of skeletal muscle was significantly suppressed. Conclusion: L-carnitine suppresses loss of skeletal muscle mass and may therefore be a novel therapeutic option for sarcopenia in patients with LC.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 須田 剛生

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University